This trial is testing a new cancer drug to see if it is safe and works well against cancer cells.
5 Primary · 26 Secondary · Reporting Duration: Up to 43 months
Experimental Treatment
366 Total Participants · 4 Treatment Groups
Primary Treatment: Ribociclib · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: